College of Traditional Chinese Medicine, Changchun University of Chinese Medicine, 130117 Changchun, Jilin, China.
Department of Cardiology, The Affiliated Hospital of Changchun University of Chinese Medicine, 130021 Changchun, Jilin, China.
Discov Med. 2024 May;36(184):1070-1079. doi: 10.24976/Discov.Med.202436184.99.
Atherosclerosis (AS) is a chronic inflammatory vascular disease with a complex pathogenesis. Astragaloside IV (AST IV), the primary active component of Astragalus, possesses anti-inflammatory, antioxidant, and immunomodulatory properties. This research aims to investigate the outcome of AST IV on AS and its potential molecular mechanism.
A high-fat diet (21% fat, 50% carbohydrate, 20% protein, 0.15% cholesterol, and 34% sucrose) was utilized to feed Apolipoprotein E deficient (ApoE) SD rats for 8 weeks, followed by continuous intragastric administration of AST IV for 8 weeks. Biochemical detection was conducted for serum lipid levels and changes in vasoactive substances. After Masson staining, aortic root oil red O staining, and Hematoxylin Eosin (HE) staining, the efficacy of AST IV was verified using quantitative reverse transcription polymerase chain reaction (qRT-PCR). The mRNA expression levels of inflammatory factors and endothelial dysfunction-related biomarkers in rat aortic root tissues were appraised. The changes in the composition of intestinal flora in rats after AST IV treatment were appraised using Image J (Multi-point Tool). Western blot was used to evaluate phosphatidylinositol-3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/Akt/mTOR) pathway-related protein levels in rat aortic root tissues.
AST IV administration alleviated the pathological symptoms of AS rats. AST IV administration reduced serum total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), endothelin-1 (ET-1) and angiotensin (Ang)-II (Ang-II) levels, and augmented serum high-density lipoprotein cholesterol (HDL-C) and nitric oxide (NO) levels. At the same time, AST IV administration inhibited the levels of tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), IL-1β, vascular cell adhesion molecule-1 (VCAM-1), matrix metalloproteinase-2 (MMP-2), macrophage inflammatory protein-1 (MCP-1), and intercellular adhesion molecule-1 (ICAM-1) in the aortic root tissue of AS rats. In addition, the intestinal flora changed significantly after AST IV administration. The number of Bifidobacterium, Lactobacillus, and Bacteroides augmented significantly, and , , , and significantly decreased. Mechanistically, AST IV administration inhibited the phosphorylation of PI3K, Akt, and mTOR in AS rats. When combined with Dactolisib (BEZ235) (a PI3K/Akt/mTOR pathway inhibitor), AST IV could further inhibit phosphorylation and reduce inflammation.
AST IV has a potential anti-AS effect, which can improve the pathological changes of the aorta in ApoE rats fed with a high-fat diet, reduce the level of inflammatory factors, and modulate the composition of intestinal flora via the PI3K/Akt/mTOR pathway.
动脉粥样硬化(AS)是一种复杂发病机制的慢性炎症性血管疾病。黄芪甲苷(AST IV)是黄芪的主要活性成分,具有抗炎、抗氧化和免疫调节作用。本研究旨在探讨 AST IV 对 AS 的作用及其潜在的分子机制。
采用高脂饮食(21%脂肪、50%碳水化合物、20%蛋白质、0.15%胆固醇和 34%蔗糖)喂养载脂蛋白 E 缺陷(ApoE)SD 大鼠 8 周,然后连续给予 AST IV 灌胃 8 周。通过生化检测血清脂质水平和血管活性物质的变化。通过主动脉根部油红 O 染色、Masson 染色和苏木精-伊红(HE)染色,用定量逆转录聚合酶链反应(qRT-PCR)验证 AST IV 的疗效。评估大鼠主动脉根部组织中炎症因子和内皮功能障碍相关生物标志物的 mRNA 表达水平。使用 Image J(多点工具)评估 AST IV 处理后大鼠肠道菌群的组成变化。使用 Western blot 评估大鼠主动脉根部组织中磷脂酰肌醇-3-激酶/蛋白激酶 B/哺乳动物雷帕霉素靶蛋白(PI3K/Akt/mTOR)通路相关蛋白水平。
AST IV 给药减轻了 AS 大鼠的病理症状。AST IV 给药降低了血清总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)、内皮素-1(ET-1)和血管紧张素(Ang)-II(Ang-II)水平,增加了血清高密度脂蛋白胆固醇(HDL-C)和一氧化氮(NO)水平。同时,AST IV 给药抑制了 AS 大鼠主动脉根部组织中肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)、白细胞介素-1β(IL-1β)、血管细胞黏附分子-1(VCAM-1)、基质金属蛋白酶-2(MMP-2)、巨噬细胞炎症蛋白-1(MCP-1)和细胞间黏附分子-1(ICAM-1)的水平。此外,AST IV 给药后肠道菌群发生明显变化。双歧杆菌、乳酸杆菌和拟杆菌的数量明显增加,而 、 、 、 明显减少。在机制上,AST IV 给药抑制了 AS 大鼠中 PI3K、Akt 和 mTOR 的磷酸化。当与 Dactolisib(BEZ235)(PI3K/Akt/mTOR 通路抑制剂)联合使用时,AST IV 可以通过 PI3K/Akt/mTOR 通路进一步抑制磷酸化并减少炎症。
AST IV 具有潜在的抗 AS 作用,可改善高脂饮食喂养的 ApoE 大鼠主动脉的病理变化,降低炎症因子水平,并通过 PI3K/Akt/mTOR 通路调节肠道菌群组成。